Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
This clinical study builds on the results of a previous double-blind, placebo-controlled phase II trial, which provided proof-of-concept for the ToleroMune technology. The current double-blind, placebo-controlled phase II trial will study both safety and surrogate efficacy outcomes, following escalating doses administered via two different routes (intradermal and subcutaneous). The study is taking place in Germany in up to 11 patient cohorts, with each containing 8 subjects with cat-dander allergy. Trial recruitment is progressing rapidly, and dosing is complete in the first patient cohort and ongoing in the second and third groups of patients.
"With clinical proof-of-concept already established for our ToleroMune technology, this phase II study will provide us with valuable data on both the most appropriate route of administration and dose optimization, which should be applicable across our entire anti-allergy product range," said Steve Harris, Circassia's CEO. "This study is particularly important for Circassia, moving our lead product closer to market, and at the same time establishing a development pathway for our other anti-allergy products."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.